Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Acer Therapeutics Inc is a biotechnology business based in the US. Acer Therapeutics shares (ACER) are listed on the NASDAQ and all prices are listed in US Dollars. Acer Therapeutics employs 21 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Social investors
| Latest market close | $2.93 |
|---|---|
| 52-week range | $2.15 - $5.84 |
| 50-day moving average | $2.73 |
| 200-day moving average | $3.08 |
| Wall St. target price | $10.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.20 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.93 from 2021-05-28
| 1 week (2021-07-25) | N/A |
|---|---|
| 1 month (2021-07-02) | 2.45% |
| 3 months (2021-05-05) | 7.72% |
| 6 months (2021-02-01) | N/A |
| 1 year (2020-08-01) | N/A |
|---|---|
| 2 years (2019-08-01) | N/A |
| 3 years (2018-08-01) | N/A |
| 5 years (2016-08-01) | N/A |
| Revenue TTM | $4 million |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -39.64% |
| Return on equity TTM | -158.78% |
| Profit margin | 0% |
| Book value | $0.73 |
| Market capitalisation | $34.6 million |
TTM: trailing 12 months
There are currently 45,327 Acer Therapeutics shares held short by investors – that's known as Acer Therapeutics's "short interest". This figure is 9.1% down from 49,883 last month.
There are a few different ways that this level of interest in shorting Acer Therapeutics shares can be evaluated.
Acer Therapeutics's "short interest ratio" (SIR) is the quantity of Acer Therapeutics shares currently shorted divided by the average quantity of Acer Therapeutics shares traded daily (recently around 64752.857142857). Acer Therapeutics's SIR currently stands at 0.7. In other words for every 100,000 Acer Therapeutics shares traded daily on the market, roughly 700 shares are currently held short.
However Acer Therapeutics's short interest can also be evaluated against the total number of Acer Therapeutics shares, or, against the total number of tradable Acer Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acer Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Acer Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0057% of the tradable shares (for every 100,000 tradable Acer Therapeutics shares, roughly 6 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Acer Therapeutics.
Find out more about how you can short Acer Therapeutics stock.
We're not expecting Acer Therapeutics to pay a dividend over the next 12 months.
Acer Therapeutics's shares were split on a 96:1000 basis on 20 September 2017. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 96 shares. This wouldn't directly have changed the overall worth of your Acer Therapeutics shares – just the quantity. However, indirectly, the new 941.7% higher share price could have impacted the market appetite for Acer Therapeutics shares which in turn could have impacted Acer Therapeutics's share price.
Over the last 12 months, Acer Therapeutics's shares have ranged in value from as little as $2.15 up to $5.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acer Therapeutics's is 1.1796. This would suggest that Acer Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Acer Therapeutics Inc. , a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 2013 and is headquartered in Newton, Massachusetts. .
Everything we know about the Chobani IPO, plus information on how to buy in.
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
